Hsin-Hung Chen

Dr. Hsin-Hung Chen

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
SCShih-Hong Chen
Shih-Hong Chen
TLTe-I Liu
Te-I Liu
CCCheng-Lin Chuang
Cheng-Lin Chuang
HCHsin-Hung Chen
Hsin-Hung Chen
Wen-Hsuan ChiangWen-Hsuan Chiang
Wen-Hsuan Chiang
CCChi-Shiun Chiang
Chi-Shiun Chiang
To considerably enhance treatment efficacy for bone metastatic breast cancer via dual bone/tumor-targeted chemotherapy, a nanoparticle-based delivery system comprising poly(lactic-co-glycolic acid) (PLGA) as the hydrophobic core coated with alendronate-modified D-α-tocopheryl polyethylene glycol succinate (ALN-TPGS) and folic acid-conjugated TPGS (FA-TPGS) was developed as a vehicle for paclitaxel (PTX) in this work. The ALN/FA-decorated nanoparticles not only showed superior ALN-mediated binding affinity for hydroxyapatite abundant in bone tissue but also promoted uptake of payloads by folate receptor-overexpressing cancer cells to significantly augment PTX cytotoxicity. Notably, through dual-targetable delivery to the bone matrix and folate receptor-overexpressing 4T1 tumors, the PTX-loaded nanoparticles substantially accumulated in bone metastases in vivo and inhibited 4T1 tumor growth and lung metastasis, leading to significant improvement of the survival rate of treated mice. Upon treatment with the ALN/FA-decorated PTX-loaded nanoparticles, the bone destruction and bone loss of the tumor-bearing mice were appreciably retarded, and the adverse effects on normal tissues were alleviated. These results demonstrate that the ALN/FA-decorated PTX-loaded delivery system developed in this study shows great promise for the effective treatment of bone metastatic breast cancer.

1 October 2020 in Biomaterials
Verified
Journal Article
Closed access
TLTe-I Liu
Te-I Liu
TLTing-Yu Lu
Ting-Yu Lu
YYYing-Chieh Yang
Ying-Chieh Yang
SCSiou-Han Chang
Siou-Han Chang
HCHsin-Hung Chen
Hsin-Hung Chen
CCChi-Shiun Chiang
Chi-Shiun Chiang

29 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HCHsin-Hung Chen
Hsin-Hung Chen
CSChen-Hsiang Sang
Chen-Hsiang Sang
CCChang-Wei Chou
Chang-Wei Chou
YLYi-Ting Lin
Yi-Ting Lin
YCYi-Shou Chang
Yi-Shou Chang
CCChi-Shiun Chiang
Chi-Shiun Chiang
Pneumonia stands as the leading infectious cause of childhood mortality annually, underscoring its significant impact on pediatric health. Although dexamethasone (DXMS) is effective for treating pulmonary inflammation, its therapeutic potential is compromised by systemic side effects and suboptimal carrier systems. To address this issue, the current study introduces solid lipid nanoparticles encapsulating hydrophobic dexamethasone palmitate (DXMS-Pal-SLNs) as an anti-inflammatory nanoplatform to treat pneumonia. The specialized nanoparticle formulation is characterized by high drug loading efficiency, low drug leakage and excellent colloidal stability in particular during nebulization and is proficiently designed to target alveolar macrophages in deep lung regions via local delivery with the nebulization administration. In vitro analyses revealed substantial reductions in the secretions of tumor necrosis factor-α and interleukin-6 from alveolar macrophages, highlighting the potential efficacy of DXMS-Pal-SLNs in alleviating pneumonia-related inflammation. Similarly, in vivo experiments showed a significant reduction in the levels of these cytokines in the lungs of mice experiencing lipopolysaccharide-induced pulmonary inflammation after the administration of DXMS-Pal-SLNs via nebulization. Furthermore, the study demonstrated that DXMS-Pal-SLNs effectively control acute infections without causing pulmonary infiltration or excessive recruitment of immunocytes in lung tissues. These findings highlight the potential of nebulized DXMS-Pal-SLNs as a promising therapeutic strategy for mitigating pneumonia-related inflammations.

1 January 2017 in Theranostics
Verified
Journal Article
Open access
CHChia-Chian Hung
Chia-Chian Hung
WHWen-Chia Huang
Wen-Chia Huang
YLYi-Wen Lin
Yi-Wen Lin
TYTing-Wei Yu
Ting-Wei Yu
HCHsin-Hung Chen
Hsin-Hung Chen
CCChi-Shiun Chiang
Chi-Shiun Chiang
[This corrects the article on p. 302 in vol. 6, PMID: 26909107.].

1 February 2016 in Journal of Alloys and Compounds
Verified
Journal Article
Closed access
CSChia-Chieh Shen
Chia-Chieh Shen
CWChung-Min Wang
Chung-Min Wang
HCHsin-Hung Chen
Hsin-Hung Chen

21 March 2005
Verified
Conference Paper
Closed access
HCHsin-Hung Chen
Hsin-Hung Chen
CWChau-Chang Wang
Chau-Chang Wang
FHFu-Chuan Hung
Fu-Chuan Hung